Journal
DIABETES CARE
Volume 40, Issue 7, Pages 966-972Publisher
AMER DIABETES ASSOC
DOI: 10.2337/dc16-2747
Keywords
-
Categories
Funding
- Novo Nordisk
- Eli Lilly
- Bristol-Myers Squibb
- GI Dynamics
- Elcelyx
- Merck
- Metavention
- vTv Therapeutics
- PhaseBio
- AstraZeneca
- Dance Biopharm
- Quest Diagnostics
- Sanofi
- Lexicon Pharmaceuticals
- Orexigen Therapeutics
- Takeda Pharmaceuticals
- Adocia
- Roche
- Medtronic
- Tolerex
- Osiris Therapeutics
- Halozyme Therapeutics
- Johnson Johnson
- Andromeda
- Boehringer Ingelheim
- GlaxoSmithKline
- Astellas Pharma
- MacroGenics
- Intarcia Therapeutics
- Lexicon
- Scion NeuroStim
- Theracos
- Berlin-Chemie
- Merck Sharp Dohme
- Versartis
- Novartis
- Janssen
- Medscape
Ask authors/readers for more resources
OBJECTIVE To evaluate serum amylase and lipase levels and the rate of acute pancreatitis in patients with type 2 diabetes and high cardiovascular risk randomized to liraglutide or placebo and observed for 3.5-5.0 years. RESEARCH DESIGN AND METHODS A total of 9,340 patients with type 2 diabetes were randomized to either liraglutide or placebo (median observation time 3.84 years). Fasting serum lipase and amylase were monitored. Acute pancreatitis was adjudicated in a blinded manner. RESULTS Compared with the placebo group, liraglutide-treated patients had increases in serum lipase and amylase of 28.0% and 7.0%, respectively. Levels were increased at 6 months and then remained stable. During the study, 18 (0.4% [1.1 events/1,000 patient-years of observation] [PYO]) liraglutide-treated and 23 (0.5% [1.7 events/1,000 PYO]) placebo patients had acute pancreatitis confirmed by adjudication. Most acute pancreatitis cases occurred >= 12 months after randomization. Liraglutide-treated patients with prior history of pancreatitis (n = 147) were not more likely to develop acute pancreatitis than similar patients in the placebo group (n = 120). Elevations of amylase and lipase levels did not predict future risk of acute pancreatitis (positive predictive value < 1.0%) in patients treated with liraglutide. CONCLUSIONS In a population with type 2 diabetes at high cardiovascular risk, there were numerically fewer events of acute pancreatitis among liraglutide-treated patients (regardless of previous history of pancreatitis) compared with the placebo group. Liraglutide was associated with increases in serum lipase and amylase, which were not predictive of an event of subsequent acute pancreatitis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available